OOIR: Observatory of International Research

Papers

(The TQCC of RMD Open is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan	131
Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupu	118
Associations of pain sensitisation with tender and painful joint counts in people with hand osteoarthritis: results from the Nor-Hand study	100
COVID-19 infection among patients with autoinflammatory diseases: a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI – the French cohort study of SARS-CoV-2	94
Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cr	80
Identification of variants in genes associated with autoinflammatory disorders in a cohort of patients with psoriatic arthritis	79
Antirheumatic treatment, disease activity and risk ofStaphylococcus aureusbacteraemia in rheumatoid arthritis: a nationwide nested case–control study	65
Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study	64
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 tri	60
Correction: Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider	55
CD73^lowB-cell phenotypes and distinct cytokine profiles in patients with active anti-Jo-1 antibody positive idiopathic inflammatory myopathies	54
Correction: Multicentrer study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results	54
Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study	53
Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use	50
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination	48
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2	48
Social media in advancing equity and collaboration in rheumatology: the CORDIALITY review	47
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study	46
Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study	45
Assessment and personalised advice for fatigue in systemic lupus erythematosus using an innovative digital tool: the Lupus Expert system for the Assessment of Fatigue (LEAF) study	45
Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study	45
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry	44
Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism	44
Concordance and agreement between different activity scores in polymyalgia rheumatica	43
Gut microbiome and intestinal inflammation in preclinical stages of rheumatoid arthritis	43

Long-term effectiveness of a lifestyle intervention for rheumatoid arthritis and osteoarthritis: 1-year follow-up of the ‘Plants for Joints’ randomised clinical trial	42
Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry	39
Still’s disease continuum from childhood to elderly: data from the international AIDA Network Still’s disease registry	34
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials	34
Minimally invasive ultrasound-guided biopsy of the common extensor tendon enthesis: a cadaveric study to standardise the technique	33
High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex	33
Bilateral swelling of the salivary glands and sicca symptoms: an unusual differential diagnosis—Kimura’s disease, a rare allergic condition with a high IgE serum level—a case report and review of the	32
Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany	32
Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment	30
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance	30
History of pre-eclampsia does not appear to be a risk factor for vascular phenotype in women with systemic sclerosis	29
Tolerability of low to moderate biomechanical stress during leisure sport activity in patients with psoriasis and psoriatic arthritis	29
Comparison between primary Sjögren’s disease patients with high or low level of dryness	29
Trends in work participation among patients with inflammatory rheumatic musculoskeletal diseases (iRMDs): Data from the German National Database (2010–2022)	29
Chronic abdominal aortic occlusive disease related to antiphospholipid syndrome: a rare presentation	29
Correction: Dissecting signalling pathways associated with intrarenal synthesis of complement components in lupus nephritis	28
Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study	28
A Thermographic Disease Activity Index for remote assessment of rheumatoid arthritis	27
Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis	27
Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study	27
Biomechanical determinants of rheumatoid arthritis severity and excess cardiovascular disease: common origins of two complex diseases	27
Engagement and attrition with eHealth tools for remote monitoring in chronic arthritis: a systematic review and meta-analysis	27
Pain sensitisation and joint inflammation in patients with active rheumatoid arthritis	26
Moderate and high disease activity levels increase the risk of subclinical atherosclerosis progression in early rheumatoid arthritis: a 5-year prospective study	26
Personalised care packages for people with rheumatoid arthritis: a mixed-methods study	26
Correction: Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study	26
Gender equity in academic rheumatology: is there a gender gap at European rheumatology conferences?	25
Immune reactivity directed against the carbamylated fibrinogen α chain does not cross-react with citrullinated fibrinogen immunodominant peptides in patients with rheumatoid arthritis	25
Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritis	24
Neuropathic pain in the IMI-APPROACH knee osteoarthritis cohort: prevalence and phenotyping	24
Diagnostic accuracy in axial spondyloarthritis: a systematic evaluation of the role of clinical information in the interpretation of sacroiliac joint imaging	24
Correction: Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long- term extension study	24
Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observati	24
Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral	24
Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND	24
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inf	23
The development and initial validation of IgG4-related disease damage index: a consensus report from Chinese IgG4-RD Consortium	23
Waiting for JAK inhibitor safety data	23
Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated	22
Neoehrlichia mikurensisis uncommon in rheumatological patients receiving tumour necrosis factor inhibitors and in blood donors: a retrospective cohort study	22
Spontaneous resolution of acute gout: mechanisms and therapeutic targets	22
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study	22
Targeting the IL-17A pathway for therapy in early-stage tendinopathy	22
Allergic conditions and risk of rheumatoid arthritis: a Swedish case–control study	22
Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observatio	22
Performances of machine learning algorithms in discriminating sacroiliitis features on MRI: a systematic review	22
JAK inhibition and the holy grail for pain control in early RA	22
Patients with osteoporosis: children of a lesser god	21
Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment	21
Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference	21

Safe use of tocilizumab in pregnant women with Takayasu arteritis: three case studies	21
Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study	21
Genetic dissection ofHLA-DRB115:01and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role forHLA-DRB115:01	20
Correction: Impact of filgotinib on pain control in the phase 3 FINCH studies	20
Chronic kidney disease in patients with psoriatic arthritis: a cohort study	20
What are the hot topics in Japanese rheumatology? Go above and beyond	20
Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study	20
Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study	20
Identification of the first signs or symptoms in different spondyloarthritis subtypes and their association with HLA-B27: data from REGISPONSER and RESPONDIA registries	20
Rituximab to treat prolidase deficiency due to a novel pathogenic copy number variation inPEPD	20
Acetylated bacterial proteins as potent antigens inducing an anti-modified protein antibody response	20
Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus	19
Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients	19
Systematic screening for multimorbidities in patients with inflammatory rheumatic diseases enhanced preventive medication use and reduced hospitalisations: an exposed-non-exposed study	19
Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study	19
Association of peripheral CD8⁺T cell activation with disease activity and treatment resistance in systemic lupus erythematosus	19
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension	19
Rheumatoid arthritis and psoriatic arthritis: is the disease impact different? A large matching study at diagnosis and after 1 year of treatment	19
COVID-19-associated arthritis: an emerging new entity?	19
Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and mic	19
Work loss in patients with rheumatoid arthritis treated with abatacept, rituximab, tocilizumab or TNF inhibitors: a nationwide direct drug-to-drug comparison	18
External validation of the 2022 ACR/EULAR classification criteria in patients with suspected giant cell arteritis in a Dutch fast-track clinic	18
Active counselling and well-controlled disease result in a higher percentage of women with rheumatoid arthritis that breast feed: results from the PreCARA study	18
Diffusing capacity of lungs for carbon monoxide associated with subclinical myocardial impairment in systemic sclerosis: A cardiac MR study	18
Is there a mitochondrial DNA haplogroup connection between osteoarthritis and elite athletes? A narrative review	18
Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort	18
In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora	18
Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients	18
Levelling the playing field of RMD research across Europe to address patients’ needs: the emerging EULAR Research Centre	18
Premature coronary artery disease in patients with immune-mediated inflammatory disease: a population-based study	18
Fetal and maternal morbidity in pregnant patients with Lupus: a 10-year US nationwide analysis	18
Prediction of progressive fibrosing interstitial lung disease in patients with systemic sclerosis: insight from the CRDC cohort study	18
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea	18
Third dose corrects waning immunity to SARS-CoV-2 mRNA vaccines in immunocompromised patients with immune-mediated inflammatory diseases	18
New pro-inflammatory cytokine IL-40 is produced by activated neutrophils and plays a role in the early stages of seropositive rheumatoid arthritis	18
Clinically relevant differences in spinal mobility related to daytime performance in patients with axial spondyloarthritis	18
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study	18
Worse long-term renal outcome of lupus nephritis patients of African descent living in Europe	18
Arrhythmia in patients with systemic sclerosis: incidence, risk factors and impact on mortality in a Swedish register-based study	18
Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider	18
Erdheim-Chester disease with Rosai-Dorfman-like lesions: treatment with methotrexate, anakinra and upadacitinib	17
Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study	17
Do fatty lesions explain the effect of inflammation on new syndesmophytes in patients with radiographic axial spondyloarthritis? Results from the SIAS cohort and ASSERT trial	17
Myocardial infarction in ANCA-associated vasculitis: a population-based cohort study	17
Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease	17
Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study	17
Primary antibody deficiency-associated arthritis shares features with spondyloarthritis and enteropathic arthritis	17
Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network	17
Celebrating the global impact of rheumatology research: preface to the Viewpoint Article—‘What are the hot topics in Japanese rheumatology?—Go above and beyond’ by Yoshiya Tanaka, Japan	17
Routine radiographs of hands and feet do not have diagnostic or prognostic value in patients with clinically suspect arthralgia: a large longitudinal study	17
Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)	17
Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical p	17
Determinants of radiographic progression in early psoriatic arthritis: insights from a real-world cohort	16
Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades	16
Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren’s disease	16
Free educational material on the EULAR school of rheumatology website	16
Correction: Ultrasound assessment of degenerative muscle Sarcopenia: the university of barcelona ultrasound scoring system for Sarcopenia	16
Step forward in early recognition of systemic sclerosis: data from the Leiden CCISS cohort	16
Correction: Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance	16
Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis	16
Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis	16
CT informs detection and treatment options in rheumatoid arthritis complicated by pulmonary non-tuberculous mycobacterial disease from the FIRST registry	16
Pilot study of tocilizumab monotherapy for active chronic periaortitis	16
Evaluating the participation of junior members and patient and healthcare professionals representatives in EULAR task forces: results from an international survey	16
Exploring the macro-level, meso-level and micro-level barriers and facilitators to the provision of good quality early inflammatory arthritis (EIA) care in England and Wales	16
MUC5Bpromoter variant rs35705950, rare but significant susceptibility locus in rheumatoid arthritis-interstitial lung disease with usual interstitial pneumonia in Asian populations	15
Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study	15
Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial	15
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis	15
Mining the pathogenesis of rheumatoid arthritis, the leading role of the environment	15
Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polya	15
Gut-joint axis in knee synovitis: gut fungal dysbiosis and altered fungi–bacteria correlation network identified in a community-based study	15
EULAR points to consider for including the perspective of young patients with inflammatory arthritis into patient-reported outcomes measures	15
Methotrexate inhibits glucocorticoids-induced osteoclastogenesis via activating IFN-γR/STAT1 pathway in the treatment of rheumatoid arthritis	15
Integration of transcriptome and immunophenotyping data highlights differences in the pathogenetic kinetics of B cells across immune-mediated disease	15
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study	15
Impact of the COVID-19 pandemic on work productivity in patients with spondyloarthritis: results from the Dutch SpA-Net registry	15
Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review	15
Metabolic and molecular imaging in inflammatory arthritis	14
Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses	14

Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies	14
Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey	14
Effectiveness of remote care interventions: a systematic review informing the 2022 EULAR Points to Consider for remote care in rheumatic and musculoskeletal diseases	14
Anti-dsDNA IgE: a potential non-invasive test for prediction of lupus nephritis relapse	14
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis	14
Incidence of collagen-induced arthritis is elevated by a high-fat diet without influencing body weight in mice	14
Severe methotrexate toxicity in elderly patients under diuretics	14
Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task force	14
Reappraisal of large artery involvement in giant cell arteritis: a population-based cohort over 70 years	14
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study	14
Burden of coronary artery calcification in ANCA-associated vasculitis	13
Health-related quality of life and disability in adults with juvenile idiopathic arthritis: comparison with adult-onset rheumatic diseases	13
Course of paediatric ANCA-associated glomerulonephritis: advocating for an age-inclusive approach	13
Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis	13
Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination	13
Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLO	13
Hyperactivation and altered selection of B cells in patients with paediatric Sjogren’s syndrome	13
Depression, anxiety and cognitive function in persons with inflammatory rheumatic diseases: cross-sectional results from the German National Cohort (NAKO)	13
Venous vessel-wall assessment with superb microvascular imaging in Behçet syndrome	13
Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts	13
Correction: miRNAs as potential biomarkers for subclinical atherosclerosis in sjögren’s disease	13
Is the Rheumatoid Arthritis Impact of Disease (RAID) score a meaningful instrument for other inflammatory rheumatic diseases? A cross-sectional analysis of data from the German National Database	13
Sustained complete B cell depletion is associated with rituximab efficacy in connective tissue disorders-associated interstitial lung disease	13
Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial	13
Increased prevalence of hearing loss, tinnitus and sudden deafness among patients with Sjögren’s syndrome	13
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks o	13
Large language model-driven sentiment analysis for facilitating fibromyalgia diagnosis	13
Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study	13
Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce	13
Association between hyperuricaemia and hand osteoarthritis: data from the Xiangya Osteoarthritis Study	13
Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib	12
Use and detailed metric properties of patient-reported outcome measures for rheumatoid arthritis: a systematic review covering two decades	12
Same, same or different? Commonalities and differences between spondyloarthritis and its subsets of axial and peripheral spondyloarthritis with psoriatic arthritis and its diverse phenotypes	12
Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: a systematic review following COSMIN guidelines	12
Inflammation in the posterior elements, in particular the facet joint and facet joint ankylosis over 2-year follow-up in radiographic axial spondyloarthritis	12
Contrasting role of NLRP12 in autoinflammation: evidence from a case report and mouse models	12
Large language models for accurate disease detection in electronic health records: the examples of crystal arthropathies	12
Need and value of targeted immunosuppressive therapy in giant cell arteritis	12
Endothelial dysfunction and increased carotid intima–media thickness in patients with spondyloarthritis without traditional cardiovascular risk factors	12
Grip strength reduction in clinically suspect arthralgia: natural trajectories and improvement after treatment	12
Low prevalence of anti-SSA (anti-Ro) and anti-SSB (anti-La) autoantibodies in female patients with rheumatoid arthritis with a wish to conceive	12
Baseline clinical characteristics of predicted structural and pain progressors in the IMI-APPROACH knee OA cohort	12
Safety, patient acceptance and diagnostic accuracy of ultrasound core needle biopsy of parotid or submandibular glands in primary Sjögren’s syndrome with suspected salivary gland lymphoma	12
Association of aFAM13Avariant with interstitial lung disease in Japanese rheumatoid arthritis	12
Computable phenotype for real-world, data-driven retrospective identification of relapse in ANCA-associated vasculitis	12
Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening	11
Primary Sjögren’s syndrome independently promotes premature subclinical atherosclerosis	11
Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews	11
Distribution patterns of arterial affection and the influence of glucocorticoids on ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in patients with giant cell arteritis	11
Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis	11
Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials	11
Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis	11
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis	11
Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis	11
Hand osteoarthritis is associated with limitations in paid and unpaid work participation and related societal costs: the HOSTAS cohort	11
Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden	11
Characteristics and outcome of critically ill patients with systemic rheumatic diseases referred to the intensive care unit	11
Eosinopenia and routine inflammatory biomarkers are helpful for the diagnosis of infection in patients treated with IL-6 pathway antagonists	11
Correction: Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody	11
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III,	11
The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials	11
Patients with VEXAS diagnosed in a Danish tertiary rheumatology setting have highly elevated inflammatory markers, macrocytic anaemia and negative autoimmune biomarkers	11
Impact of rheumatoid arthritis and methotrexate on pregnancy outcomes: retrospective cohort study of the Italian Society for Rheumatology	11
Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease	11
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project	11
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression	11
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider	11
Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial	11
Identification of patient endotypes and adalimumab treatment responders in axial spondyloarthritis using blood-derived extracellular matrix biomarkers	11
Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial	11
Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry	11
Correction: Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study	11
Porphyromonas gingivalisassociates with the presence of anti-citrullinated protein antibodies, but not with the onset of arthritis: studies in an at-risk population	11
Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition	11
Long delay from symptom onset to first consultation contributes to permanent vision loss in patients with giant cell arteritis: a cohort study	10
Cancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish register-based cohort study	10
Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study	10
Utilisation of cardiovascular preventive services in a rheumatoid arthritis population-based cohort	10
Lumbar interspinous bursitis in a patient with polymyalgia rheumatica/giant cell arteritis detected by musculoskeletal ultrasound: a case report	10
Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats	10
Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective	10
Factors influencing the kinetics of MSU crystal depletion measured with dual-energy CT in patients with gout	10
Disease modification achievement in patients with lupus nephritis in a real-life setting: mission impossible?	10
Frailty is independently associated with subclinical cardiovascular disease in patients with systemic lupus erythematosus	10
EULAR standardised training model for ultrasound-guided, minimally invasive synovial tissue biopsy procedures in large and small joints	10
Association between sinusitis and incident rheumatic diseases: a population-based study	10
Joint distraction using a purpose-built device for knee osteoarthritis: a prospective 2-year follow-up	10
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study	10
The wide range of opportunities for large language models such as ChatGPT in rheumatology	10
Polygenic risk score: the potential role in the management of systemic lupus erythematosus	10
Disease evolution and organ damage accrual in patients with stable UCTD: a long-term monocentric inception cohort	10
Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study	10
In early rheumatoid arthritis, comorbidities do not explain the increased risk of failure to reach remission in patients with obesity	10
Effect of high-intensity interval training in physiotherapy primary care for patients with inflammatory arthritis: the ExeHeart randomised controlled trial	10
Assessment of type I interferon response in routine practice in France in 2022	10